Market research
PAS.V Pascal Biosciences Inc
V CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 984K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.51
Profile
Company facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA7024781089
- Market cap
- 984K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.51
About
About Pascal Biosciences Inc
Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PAS.V discussion.
5 years, 5 months ago
Pascal Biosciences Inc is currently in a long term downtrend where the price is trading 19.9% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Pascal Biosciences Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 39.1% to $-320K since the same quarter in the previous year.
Finally, its free cash flow grew by 79.7% to $-109K since the same quarter in the previous year.
Based on the above factors, Pascal Biosciences Inc gets an overall score of 3/5.